High Court Asked To Review 2nd Circ. Fosamax Ruling

Law360, New York (May 1, 2013, 7:58 PM EDT) -- A one-time user of the bone drug Fosamax urged the U.S. Supreme Court on Wednesday to review the Second Circuit's ruling in favor of Merck & Co. in multidistrict litigation over the medication, blasting the appeals court for discrediting her physician's testimony as a sham.

A Second Circuit panel refused to order a retrial in the case, one of seven bellwethers in the litigation, in January. Plaintiff Linda Secrest claimed her use of Fosamax between 1998 and 2005 caused her to develop osteonecrosis of the jaw...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.